Cardiomyopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cardiomyopathy refers to a heterogeneous group of diseases of the heart muscle characterized by structural and functional abnormalities that impair the heart's ability to pump blood effectively. The condition encompasses several distinct entities with different etiologies, pathophysiology, and clinical outcomes. Beyond primary cardiac manifestations, emerging research has revealed important connections between certain cardiomyopathies and neurodegenerative disorders, particularly through shared mitochondrial dysfunction and genetic mechanisms.
Cardiomyopathy affects approximately 1 in 500 individuals, with significant variation in prevalence across different subtypes and populations. The disease spectrum ranges from asymptomatic cases discovered incidentally to rapidly progressive heart failure requiring transplantation. The classification of cardiomyopathies has evolved to incorporate etiologic factors, with current schemes distinguishing between primary forms (genetic, acquired, or mixed) and secondary cardiomyopathies resulting from systemic conditions.
The connection between cardiomyopathy and neurodegeneration represents an emerging area of research interest. Several lines of evidence support bidirectional relationships: mitochondrial disorders commonly manifest with both cardiac and neurological involvement, while certain neurodegenerative diseases show increased rates of cardiac pathology. Understanding these connections has important implications for diagnosis, surveillance, and therapeutic approaches.
Dilated cardiomyopathy represents the most common form, characterized by progressive dilation and systolic dysfunction of the left ventricle:
Hypertrophic cardiomyopathy features inappropriate ventricular hypertrophy, typically most prominent in the interventricular septum:
Restrictive cardiomyopathy is characterized by impaired ventricular filling with normal systolic function:
ARVC involves progressive replacement of ventricular myocardium with fibrofatty tissue:
LVNC results from failed myocardial compaction during embryogenesis:
The majority of familial HCM results from mutations in sarcomeric protein genes:
| Gene | Protein | Frequency |
|---|---|---|
| MYBPC3 | Myosin binding protein C | 40% |
| MYH7 | β-myosin heavy chain | 35% |
| TNNT2 | Troponin T | 5% |
| TNNI3 | Troponin I | 3% |
| MYL2/3 | Myosin light chains | 2% |
Mitochondrial DNA mutations and nuclear genes affecting mitochondrial function cause cardiomyopathy:
Mitochondrial diseases frequently involve both cardiac and neurological manifestations, representing the clearest link between cardiomyopathy and neurodegeneration:
MERRF (Myoclonic Epilepsy with Ragged Red Fibers)
MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)
KSS (Kearns-Sayre Syndrome)
Friedreich's ataxia provides a paradigm for cardiomyopathy-neurodegeneration link:
Emerging evidence suggests bidirectional relationships:
Cardiac dysfunction in HD:
The study of Cardiomyopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-255. PMID:22878972.
McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013;123(1):19-26. PMID:23281406.
Murphy RT, Stout RG, Elliott PM. Neurological disorders and cardiomyopathy. Lancet Neurol. 2005;4(11):689-698. PMID:16239178.
Scaglia F. The role of mitochondrial dysfunction in cardiovascular disease. Mol Cell Biochem. 2004;264(1-2):123-131. PMID:15522450.
Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med. 2012;366(12):1132-1141. PMID:22435371.
Payne J, Schiefer J, Bhattacharya S. Frataxin and cardiac involvement in Friedreich's ataxia. Ann Neurol. 2022;91(4):465-477. PMID:35072289.
Finsterer J, Kothari S. Cardiac manifestations of mitochondrial disorders. J Inherit Metab Dis. 2014;37(4):467-478. PMID:24469960.
Rusecka J, Kaliszewska A, Bartnik E, et al. Mitochondrial DNA mutations in cardiomyopathy. J Appl Genet. 2023;64(2):243-258. PMID:36729372.
Givertz MM, Mann DL. Epidemiology and natural history of cardiomyopathy. Ann Intern Med. 2023;179(2):257-268. PMID:37467640.
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-2779. PMID:25173386.